Država: Australija
Jezik: engleski
Izvor: Department of Health (Therapeutic Goods Administration)
Chromium(51Cr) edetate; Chromium(51Cr)edetate
_ _ CHROMIUM(51CR)EDETATE INJECTION CODE: CJ13P TECHNICAL LEAFLET PRESENTATION A sterile solution, in water for injection, of chromium(51Cr)edetate for intravenous injection. The radioactive concentration is 3.7 MBq/ml (100 µCi/ml). The formulation contains chromium edetate at a concentration of 0.64 mg/ml, disodium edetate (1.9 mg/ml) and benzyl alcohol (10 mg/ml) as preservative. The pH of the injection is 3.5 - 5.0. The product is a diagnostic radiopharmaceutical supplied as a multidose vial containing 37 MBq (1 mCi). All activities quoted are to the activity reference date stated on the label. MANUFACTURER AND HOLDER OF MARKETING AUTHORISATION GE Healthcare Limited Amersham Place Little Chalfont Buckinghamshire United Kingdom INDICATION Chromium [ 51 Cr] edetate is indicated for the determination of glomerular filtration rate in the assessment of renal function. CONTRA-INDICATIONS Must not be given to premature babies or neonates. PRECAUTIONS FOR USE This medicinal product contains benzyl alcohol (10mg/ml). Benzyl alcohol may cause toxic reactions in infants and children up to 3 years old. The possibility of hypersensitivity including serious anaphylactoid reactions should always be considered. Advanced life support facilities should be readily available. To reduce the radiation dose to the bladder and an accumulation of radioactivity in it, the patient should be asked to drink additional fluids and to void the bladder as often as possible in the hours following administration. Radiopharmaceutical agents should only be used by qualified personnel with the appropriate government authorisation for the use and manipulation of radionuclides. They m Pročitajte cijeli dokument